Singapore
Singapore has moved longevity from private clinics into the mainstream of its health system, with academic programmes, hospital-backed lines, and a regulator that takes a clear position on what may be offered. variis tracks every clinic, company, and protocol in the market, and grades the evidence behind each one.
What variis tracks in Singapore
0
Clinics tracked
0
Companies tracked
0
Protocols graded
0
Specialists listed
Every figure is counted live from the Singapore records in the variis directory, and grows as the coverage does.
Dedicated regenerative-longevity.
New 2025 dedicated clinic; biohacking/therapy-heavy.
The mass-market entry tier, and the only SG operator with a full published price list. R2 correction: a screening/GP group, NOT a neutral aggregator.
The scientific reference clinic (Prof Andrea Maier). Dedicated biological-age.
AI-driven, accessibility-positioned.
Distinct premium sub-brand (biological-age evaluation, genetics). Hospital-group longevity line, secondary to the dedicated clinics.
Partial: "Precision Wellness Screening" with a Metabolic Age Report and Nightingale risk panel. Metabolic-age, NOT epigenetic biological-age.
Flagship 2026 story. US$156M (~S$201M) 5-year commitment. Licensed entity: Longevity & Lifestyle Medical Pte Ltd. Recovery wing phasing in.
Qualifies on both limbs: listed on SGX Catalist under MIJ and headquartered in Singapore (25 Bukit Batok Crescent). Alliance is an investment holding company running an integrated Singapore healthcare network: GP clinic services (My Family Clinic), specialist care, managed healthcare solutions sold to corporates and insurers, pharmaceutical services, radiology, home care (JagaMe) and a digital health app (HeyAlly). It states access to more than 2,000 in-house and partner medical facilities in Singapore, and had 395 employees with a July-June fiscal year. The longevity-relevant activity is preventive and occupational health screening delivered at scale through corporate health plans and the GP network, plus imaging and teleconsultation that route screening findings into follow-up care. It is a care-delivery and screening distribution business, not a developer of ageing-biology therapeutics or biomarker tests, so exposure is to the preventive-screening and primary-care layer rather than to any geroscience intervention.
Microbiome science company running a multi-ethnic Asian gut microbiome biobank and reference database, which it uses to interpret consumer and clinician-ordered stool tests. Commercial output is diagnostic rather than therapeutic: a gut microbiome test kit and an enhanced version, four targeted probiotic formulations (immune-metabolic, complete, cognitive, digestive), microbiome restoration therapy, and AMILI Optimise Plus, a metabolic health programme that pairs microbiome profiling with continuous glucose monitoring and nutritionist input. Distribution runs through a partner clinic network. Longevity relevance is indirect: it sits in the metabolic-health and personalised-nutrition layer, measuring and modifying a biomarker set (gut composition, glycaemic response) associated with cardiometabolic risk, not intervening in ageing biology directly. Efficacy claims for microbiome-guided nutrition remain contested in the literature; the company's own database size claims are self-reported and not independently verified here.
Operates medical clinics and diagnostic services across Singapore, the Philippines and Hong Kong, including imaging, general health screening and vaccination. Its longevity relevance is limited and indirect: it is a clinic and screening operator, not a company developing ageing-biology interventions or aging-specific biomarker panels. The relevant exposure is preventive health screening infrastructure in Southeast Asia, which sits adjacent to the longevity clinic market. Financial condition is weak: FY2025 revenue of S$9.93m was flat year on year while net loss widened to S$12.91m, and the shares trade at S$0.001 on the SGX Catalist board with a market capitalisation of roughly S$6.4m. Include only with that caveat.
Cordlife collects, processes and cryogenically stores umbilical cord blood and cord tissue for private clients across several Asian markets, operating storage facilities rather than developing therapies. Its longevity relevance is as infrastructure for cell-based and regenerative medicine: banked haematopoietic stem cells are held against future transplant or therapeutic use. It is a storage and services business, not a therapeutics developer, and it does not run clinical programmes in ageing biology. Inclusion is on the listing limb (SGX Mainboard) and the Singapore headquarters, both confirmed. Fundamentals should be treated as unconfirmed: the company is under active Singapore Ministry of Health regulatory restriction and its FY2025 accounts carry a disclaimer of opinion.
A Singapore-headquartered antibody drug developer. It designs monoclonal antibodies and antibody-drug conjugates against targets it selects computationally, then develops them for cancer and autoimmune disease. Current clinical assets are HMBD-001 (anti-HER3 antibody) and HMBD-501 (a HER3-directed antibody-drug conjugate, dosed in its first Phase I patient in January 2026). It has also out-licensed programmes: HMBD-002 (anti-VISTA) to Percheron Therapeutics in June 2025, and an undisclosed-target antibody to Immunome in January 2025. Its longevity relevance is indirect rather than direct. It does not work on ageing biology, senescence, metabolic ageing or healthspan endpoints. The connection is that cancer is a leading age-related cause of death, so better-targeted oncology therapeutics extend life in an older population. Read as an oncology biotech that sits in the SG/AU universe on headquarters grounds, not as a geroscience company.
Operates a private hospital network of 89 hospitals across 10 countries (Malaysia, Singapore, Turkiye, India, China, Hong Kong, Brunei, Bulgaria, North Macedonia, Netherlands, Serbia), including the Mount Elizabeth, Gleneagles and Parkway brands in Singapore. Its longevity relevance is delivery-side rather than therapeutic: it is the largest listed vehicle for age-related clinical care in Asia, with revenue concentrated in cardiology, oncology and orthopaedics, the specialties that scale with an ageing population. It also runs an SGD 80 million innovation fund backing startups in cancer diagnostics, digital health, proton therapy, mental health and sleep disorders. It does not develop geroprotective drugs or biological-age interventions. Inclusion is confirmed under limb (a): SGX secondary line Q0F verified on a live SGX healthcare sector listing.
Develops and sells blood-based microRNA diagnostic tests for early cancer detection. Its lead product, GASTROClear, is a 12-biomarker blood panel for gastric cancer screening; it also markets LUNGClear for lung cancer and Fortitude infectious-disease assays. The longevity relevance is early detection rather than any ageing-biology intervention: catching cancer at a screenable, asymptomatic stage in high-risk adults. Qualifies for the variis universe on the headquarters limb (Singapore), not the exchange limb, as it is listed on HKEX rather than SGX or ASX.
Clinical-stage genetic medicines company developing gene therapies for inherited cardiomyopathies, using a mechanobiology approach that targets the mechanical stress signalling inside failing heart muscle cells rather than correcting the mutated gene directly. Lead asset NVC-001 is an AAV-delivered therapy for LMNA-related dilated cardiomyopathy, an aggressive genetic heart-muscle disease with no targeted treatment. Longevity relevance is disease-specific rather than general: it aims to halt progression of a condition that causes heart failure and early death in carriers, not to modify ageing biology broadly. Both Singapore HQ and incorporation as a Pte Ltd confirmed on the company site, so it meets limb (b) of the inclusion rule.
A new clinical trial will test a community-based pathway to detect early loss of intrinsic capacity in adults aged 60 and above, supporting Singapore's Decade of Healthy Ageing Action Plan.
The PROMETHEUS study will examine tailored lifestyle, supplement, and drug approaches to counter age-related disease as global populations age.
The National University of Singapore has introduced what it describes as the world's first postgraduate program combining geroscience, gerodiagnostics and precision geromedicine in a single curriculum.
Morrow's founders argue that longevity care can move beyond elite clinics through lifestyle medicine and AI-powered approaches.
From Chi Longevity's precision health model to a new Geromedicine Conference at NUS, Singapore is positioning itself as a hub for translating longevity science into real-world clinical practice.
Across eighteen months, the region's longevity capital has taken three distinct shapes: a Melbourne clinic's seed to Series A climb, a Singapore drug discovery company's Hong Kong listing, and a five year commitment to build a flagship clinic from scratch. Together they sketch what type of longevity business Singapore and Australia capital is actually prepared to back.
Regulatory positions cite the Health Sciences Authority. Inclusion is not endorsement, and nothing here is medical advice.